Abstract
Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence. Many immunosuppressive mechanisms implicated in HCC recurrence are modulated by VEGF and/or immune checkpoints such as PD-L1. Atezolizumab (PD-L1 inhibitor) plus bevacizumab (VEGF inhibitor) has been shown to significantly improve overall survival, progression-free survival and overall response rate in unresectable HCC. Dual PD-L1/VEGF blockade may be effective in reducing HCC recurrence by creating a more immune-favorable microenvironment. We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab plus bevacizumab versus active surveillance in HCC patients at high-risk of recurrence following curative resection or ablation. The primary end point is recurrence-free survival. Clinical Trial Registration: NCT0410209.
Original language | English (US) |
---|---|
Pages (from-to) | 975-989 |
Number of pages | 15 |
Journal | Future Oncology |
Volume | 16 |
Issue number | 15 |
DOIs | |
State | Published - May 2020 |
Keywords
- Ablation
- Adjuvant treatment
- Atezolizumab
- Bevacizumab
- Hepatocellular carcinoma
- PD-L1
- Recurrence-free survival
- Resection
- VEGF
ASJC Scopus subject areas
- Oncology
- Cancer Research